Diabetes News and Research

Latest Diabetes News and Research

Minnesota lawmakers debate budget, Medicaid expansion

More budget talks were expected Thursday as Minnesota's legislative session hurtled toward a midnight Sunday deadline with no deal on a $3 billion deficit. The Democratic-controlled Legislature defied another veto threat from Republican Gov. Tim Pawlenty late Wednesday and sent him a health and welfare package he opposes.

14 May 2010

New Infrared Relief therapy now available for patients with diabetic neuropathies

Genesis Spine Associates now offers Infrared Relief - a new, highly effective pain management therapy using infrared light for patients suffering from diabetic neuropathies. This new therapy offers a simple, painless option for managing patients' pain without potentially dangerous drugs or surgery.

14 May 2010

Groups plead for more health funding as Chairman warns about cuts to proposed HHS budget

House Appropriations Committee Chairman David Obey, D-Wis., said Wednesday that groups pressing for $14 billion more in funding for education, health and labor programs will likely be disappointed because the budget proposed by President Barack Obama already faces cuts of about $3.5 billion in those areas.

14 May 2010

Derma Sciences first-quarter net sales up 23% to $12,844,382

Derma Sciences, Inc., a specialty medical device/pharmaceutical company focused on advanced wound care, reported financial and operating results today for the three months ended March 31, 2010.

14 May 2010

Repligen files IND for Phase 1 study of RG2833 selective HDAC-3 inhibitor for Friedreich's ataxia

Repligen Corporation announced today that it has filed an Investigational New Drug Application (IND) with the Food and Drug Administration (FDA) for a Phase 1 study of RG2833, a selective histone deacetylase 3 (HDAC-3) inhibitor. This is a double-blind, single ascending dose, Phase 1 study in healthy volunteers to evaluate the pharmacokinetic and safety profile of RG2833 in up to 40 subjects.

13 May 2010

Medco announces new $3 billion share repurchase program

Medco Health Solutions, Inc. today announced that its Board of Directors has unanimously approved a new $3 billion share repurchase program.

13 May 2010

Data on Qnexa to be presented at World Congress on CODHy in Prague

VIVUS, Inc. today announced that data on Qnexa, an investigational drug candidate, will be presented at the 3rd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension in Prague, Czech Republic.

13 May 2010

Researchers provide better understanding of anti-cell death proteins and potential antagonist to defeat them

Cancer uses devious means to evade treatment and survive. One prime example is the way tumors express anti-cell death (anti-apoptotic) proteins to resist chemotherapy and radiation. However, the Pellecchia laboratory at Sanford-Burnham Medical Research Institute has made two recent discoveries that may help curb these anti-apoptotic proteins and make current treatments more effective.

13 May 2010

PAREXEL further expands presence in China with offices in Chengdu and Guangzhou

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that the Company has opened offices in Chengdu and Guangzhou, China to support a growing requirement for a broad range of clinical development and regulatory consulting capabilities in the country and throughout the Asia/Pacific region.

From Parexel 13 May 2010

SAGE launches further two Therapeutic Advances journals

SAGE has extended its suite of Therapeutic Advances journals with the launch of a further two titles: Therapeutic Advances in Chronic Disease and Therapeutic Advances in Endocrinology and Metabolism.

13 May 2010

Increased IR associated with HCC development in chronic HCV-infected patients

Recent studies have demonstrated that type 2 diabetes mellitus (DM) is associated with high risk of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis C. Insulin resistance (IR), which correlates inversely with circulating adiponectin concentration, is a consistent finding in patients with type 2 DM.

13 May 2010

Researchers to discuss various implications for personalized medicine during one-day symposium

On May 27, researchers with the National Human Genome Research Institute and the National Cancer Institute, along with Group Health Cooperative in Seattle and Henry Ford Health System, will debate and discuss that question during the one-day symposium "Multiplex Initiative: Implications for Personalized Medicine."

13 May 2010

Rapid responders in novel behavior treatment for IBS maintain improvement at 3-month follow-up

Nearly one-third of patients with irritable bowel syndrome (IBS) who underwent a novel behavior treatment developed by a University at Buffalo behavioral scientist achieved significant relief within four weeks of beginning treatment.

13 May 2010

RYGB surgery increases insulin activity in diabetes mellitus patients

Diabetes mellitus is a chronic metabolic disease resulted from, either decreased production of insulin or increased resistance to it from peripheral tissues or both factors combined together. While medical treatment remains the mainstay of treatment for diabetes, some surgical procedures, such as Roux-en-Y gastric bypass, have demonstrated some potential to be a treatment option for diabetes.

13 May 2010

Additional benefits of LAIAs over long-acting human insulin not been proven

It has so far not been proven that the long-acting insulin analogues (LAIAs) insulin detemir (trade name: Levemir) and insulin glargine (trade name: Lantus), which are approved for the treatment of type 1 diabetes, offer patients an additional benefit versus long-acting human insulin. This applies to adults as well as to children and adolescents. This is the result of the final report published by the Institute for Quality and Efficiency in Health Care (IQWiG) on 19 April 2010.

13 May 2010

Study: Treating serious gum disease in diabetics can help lower blood sugar levels

Researchers have found that reducing inflammation of the gums in people with diabetes can help lower the risk of serious complications associated with the condition, such as eye problems and heart disease.

13 May 2010

Atherotech to showcase VAP Cholesterol Test at NLA Scientific Sessions 2010

Atherotech Inc. will exhibit its VAP® Cholesterol Test in booth #102 at the National Lipid Association (NLA) Scientific Sessions 2010. The meeting takes place May 13-16 at the Sheraton Hotel and Towers in Chicago.

13 May 2010

FDA should apply equal rigor in assessing food claims and drug approvals, says new report

The U.S. Food and Drug Administration should apply the same rigor to evaluating the science behind claims of foods' and nutritional supplements' health benefits as it devotes to assessing medication and medical technology approvals, says a new report from the Institute of Medicine.

13 May 2010

Computerized systems can detect early eye problems related to diabetes: UI team

People with diabetes have an increased risk of blindness, yet nearly half of the approximately 23 million Americans with diabetes do not get an annual eye exam to detect possible problems.

13 May 2010

Resverlogix' Phase 2 ASSERT trial dosing complete ahead of schedule

Resverlogix is pleased to announce that the Phase 2 ASSERT clinical trial for its lead drug, RVX-208, a small molecule therapy for the treatment of atherosclerosis has now completed dosing. "The completion of dosing for our Phase 2 ASSERT trial, five months ahead of schedule and without any alterations to the dose levels of the three drug receiving cohorts, is another major step forward in the development of this important cardiovascular drug.

13 May 2010

Diabetes News and Research

Latest Diabetes News and Research

Minnesota lawmakers debate budget, Medicaid expansion

New Infrared Relief therapy now available for patients with diabetic neuropathies

Groups plead for more health funding as Chairman warns about cuts to proposed HHS budget

Derma Sciences first-quarter net sales up 23% to $12,844,382

Repligen files IND for Phase 1 study of RG2833 selective HDAC-3 inhibitor for Friedreich's ataxia

Medco announces new $3 billion share repurchase program

Data on Qnexa to be presented at World Congress on CODHy in Prague

Researchers provide better understanding of anti-cell death proteins and potential antagonist to defeat them

PAREXEL further expands presence in China with offices in Chengdu and Guangzhou

SAGE launches further two Therapeutic Advances journals

Increased IR associated with HCC development in chronic HCV-infected patients

Researchers to discuss various implications for personalized medicine during one-day symposium

Rapid responders in novel behavior treatment for IBS maintain improvement at 3-month follow-up

RYGB surgery increases insulin activity in diabetes mellitus patients

Additional benefits of LAIAs over long-acting human insulin not been proven

Study: Treating serious gum disease in diabetics can help lower blood sugar levels

Atherotech to showcase VAP Cholesterol Test at NLA Scientific Sessions 2010

FDA should apply equal rigor in assessing food claims and drug approvals, says new report

Computerized systems can detect early eye problems related to diabetes: UI team

Resverlogix' Phase 2 ASSERT trial dosing complete ahead of schedule

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Diabetes News and Research

Latest Diabetes News and Research

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in